BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 11345654)

  • 61. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
    Smith LM; Willmore E; Austin CA; Curtin NJ
    Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Chemopotentiation by PARP inhibitors in cancer therapy.
    Tentori L; Graziani G
    Pharmacol Res; 2005 Jul; 52(1):25-33. PubMed ID: 15911331
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.
    Dilley RL; Poh W; Gladstone DE; Herman JG; Showel MM; Karp JE; McDevitt MA; Pratz KW
    Leuk Res; 2014 Mar; 38(3):411-7. PubMed ID: 24439051
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Involvement of the mismatch repair system in temozolomide-induced apoptosis.
    D'Atri S; Tentori L; Lacal PM; Graziani G; Pagani E; Benincasa E; Zambruno G; Bonmassar E; Jiricny J
    Mol Pharmacol; 1998 Aug; 54(2):334-41. PubMed ID: 9687575
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
    Kyle S; Thomas HD; Mitchell J; Curtin NJ
    Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Base excision repair proteins are required for integrin-mediated suppression of bleomycin-induced DNA breakage in murine lung endothelial cells.
    Rose JL; Reeves KC; Likhotvorik RI; Hoyt DG
    J Pharmacol Exp Ther; 2007 Apr; 321(1):318-26. PubMed ID: 17202402
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
    Miknyoczki S; Chang H; Grobelny J; Pritchard S; Worrell C; McGann N; Ator M; Husten J; Deibold J; Hudkins R; Zulli A; Parchment R; Ruggeri B
    Mol Cancer Ther; 2007 Aug; 6(8):2290-302. PubMed ID: 17699724
    [TBL] [Abstract][Full Text] [Related]  

  • 68. DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system.
    Pagani E; Pepponi R; Fuggetta MP; Prete SP; Turriziani M; Bonmassar L; Lacal PM; Falcinelli S; Passarelli F; Guadagni F; Alvino E; D'Atri S
    J Chemother; 2003 Apr; 15(2):173-83. PubMed ID: 12797396
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors.
    White AW; Curtin NJ; Eastman BW; Golding BT; Hostomsky Z; Kyle S; Li J; Maegley KA; Skalitzky DJ; Webber SE; Yu XH; Griffin RJ
    Bioorg Med Chem Lett; 2004 May; 14(10):2433-7. PubMed ID: 15109627
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide.
    Trivedi RN; Wang XH; Jelezcova E; Goellner EM; Tang JB; Sobol RW
    Mol Pharmacol; 2008 Aug; 74(2):505-16. PubMed ID: 18477668
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
    Russo AL; Kwon HC; Burgan WE; Carter D; Beam K; Weizheng X; Zhang J; Slusher BS; Chakravarti A; Tofilon PJ; Camphausen K
    Clin Cancer Res; 2009 Jan; 15(2):607-12. PubMed ID: 19147766
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.
    White AW; Almassy R; Calvert AH; Curtin NJ; Griffin RJ; Hostomsky Z; Maegley K; Newell DR; Srinivasan S; Golding BT
    J Med Chem; 2000 Nov; 43(22):4084-97. PubMed ID: 11063605
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity.
    Zhou J; Ji M; Zhu Z; Cao R; Chen X; Xu B
    Eur J Med Chem; 2017 May; 132():26-41. PubMed ID: 28340412
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy.
    Simbulan-Rosenthal CM; Rosenthal DS; Luo R; Li JH; Zhang J; Smulson ME
    Nucleic Acids Res; 2001 Feb; 29(3):841-9. PubMed ID: 11160908
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
    Palma JP; Rodriguez LE; Bontcheva-Diaz VD; Bouska JJ; Bukofzer G; Colon-Lopez M; Guan R; Jarvis K; Johnson EF; Klinghofer V; Liu X; Olson A; Saltarelli MJ; Shi Y; Stavropoulos JA; Zhu GD; Penning TD; Luo Y; Giranda VL; Rosenberg SH; Frost DJ; Donawho CK
    Anticancer Res; 2008; 28(5A):2625-35. PubMed ID: 19035287
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.
    Canan Koch SS; Thoresen LH; Tikhe JG; Maegley KA; Almassy RJ; Li J; Yu XH; Zook SE; Kumpf RA; Zhang C; Boritzki TJ; Mansour RN; Zhang KE; Ekker A; Calabrese CR; Curtin NJ; Kyle S; Thomas HD; Wang LZ; Calvert AH; Golding BT; Griffin RJ; Newell DR; Webber SE; Hostomsky Z
    J Med Chem; 2002 Nov; 45(23):4961-74. PubMed ID: 12408707
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.
    Somnay Y; Lubner S; Gill H; Matsumura JB; Chen H
    Cancer Gene Ther; 2016 Oct; 23(10):348-354. PubMed ID: 27632933
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Poly(ADP-ribose) polymerase-1 inhibition by arsenite promotes the survival of cells with unrepaired DNA lesions induced by UV exposure.
    Qin XJ; Liu W; Li YN; Sun X; Hai CX; Hudson LG; Liu KJ
    Toxicol Sci; 2012 May; 127(1):120-9. PubMed ID: 22387748
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.
    Kizilbash SH; Gupta SK; Chang K; Kawashima R; Parrish KE; Carlson BL; Bakken KK; Mladek AC; Schroeder MA; Decker PA; Kitange GJ; Shen Y; Feng Y; Protter AA; Elmquist WF; Sarkaria JN
    Mol Cancer Ther; 2017 Dec; 16(12):2735-2746. PubMed ID: 28947502
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Inhibition of poly(ADP-ribose) synthetase potentiates cell dacarbazine cytotoxicity.
    Lönn U; Lönn S
    Biochem Biophys Res Commun; 1987 Feb; 142(3):1089-94. PubMed ID: 3103613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.